Download App

Log in to access Online Inquiry
Company Overview More
Yichang East Sunshine Yangtze River Pharmaceutical Co., Ltd. is a Chinese company mainly engaged in pharmaceutical production and sales. Its business also includes drug research and development, marketing and distribution. The company's products include antiviral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its core product portfolio includes "Kewei", "er Tongshu", "European and American Ning", "Xin Haining" and "Xining".
CEO: Xinfa Tang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

01558 YiChang HEC ChangJiang Pharmaceutical
5.050-0.010-0.20%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q9)2021/09/30(Q6)2021/06/30(Q3)2021/03/31
Assets
Current assets
Inventory
-26.06% 279.7M -- -- 21.56% 392.08M -- --
Accounts receivable
-8.83% 546.79M -- -- -62.28% 391.98M -- --
Advance deposits and other receivables
-60.98% 7.78M -- -- -- 29.18M -- --
Cash and equivalents
-44.69% 1.13B -- -- -60.32% 1.33B -- --
Secured deposit
-58.41% 91.99M -- -- -- 134.21M -- --
Total current assets
-36.97% 2.06B -- -- -51.67% 2.28B -- --
Non-current assets
Fixed assets
13.43% 3.22B -- -- 40.49% 3.01B -- --
Advance payment
-89.8% 64.83M -- -- -75.32% 355.89M -- --
Financial assets at fair value-non-current assets
-- 1.79B -- -- -- -- -- --
Intangible assets
20.76% 3.27B -- -- 85.21% 3.07B -- --
Goodwill
0% 75.9M -- -- 0% 75.9M -- --
Deferred tax assets
60.7% 65.32M -- -- -3.98% 125.42M -- --
Total non-current assets
34.73% 8.48B -- -- 15.41% 6.64B -- --
Total assets
10.25% 10.54B -- 10.07B -14.78% 8.91B -- 8.91B
Liabilities
Current liabilities
Accounts payable
-27.61% 911.68M -- -- -47% 1.05B -- --
Tax payable
871.84% 198.63M -- -- -- -- -- --
Bank loans and overdrafts
-98.28% 48.48M -- -- -96.34% 13.08M -- --
Deferred income-current liabilities
0% 4.38M -- -- 85.77% 8.14M -- --
Special items of current liabilities
33.39% 74.9M -- -- -38.59% 33.15M -- --
Total current liabilities
-70.25% 1.24B -- -- -54.59% 1.1B -- --
Net current assets
191.33% 819.31M -- -- -48.55% 1.17B -- --
Total assets less current liabilities
72.29% 9.3B -- 10.07B -2.72% 7.81B -- 8.91B
Non-current liabilities
Long-term bank loan
1556.56% 3.15B -- -- 4.14% 3.07B -- --
Deferred income-non-current liabilities
29.27% 137.73M -- -- 35.92% 139.65M -- --
Total non-current liabilities
1007.56% 3.28B -- -- 5.21% 3.21B -- --
Total liabilities
1.42% 4.52B -- -- -21.31% 4.32B -- --
Total assets less total liabilities
17.97% 6.02B -- 10.07B -7.58% 4.6B -- 8.91B
Total equity and non-current liabilities
72.29% 9.3B -- -- -2.72% 7.81B -- --
Equity
Share capital
0% 879.97M -- -- 0% 879.97M -- --
Reserve
22.87% 4.93B -- -- -9.69% 3.5B -- --
Legal reserve
22.87% 4.93B -- -- -9.69% 3.5B -- --
Shareholders' Equity
18.75% 5.81B -- -- -7.9% 4.38B -- --
Non-controlling interest
-0.04% 212.48M -- -- -0.57% 212.61M -- --
Total equity
17.97% 6.02B -- -- -7.58% 4.6B -- --
Total equity and total liabilities
10.25% 10.54B -- -- -14.78% 8.91B -- --
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASCAS (2007)IASCAS (2007)
Audit Opinions
Unqualified Opinion------
Auditor
KPMG Huazhen Accounting firm (Special General Partnership)------

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%